OPTIMIZED STRAIN OF POLIOVIRUS TYPE 3 FOR THERAPY OF SOLID TUMOURS Russian patent published in 2025 - IPC C12N5/10 

FIELD: biotechnology.

SUBSTANCE: described is a method for optimizing Sabin type 3 poliovirus vaccine for selective destruction of tumour cells, involving: culturing Sabin type 3 poliovirus vaccine on a mixture of glioblastoma tumour cells, wherein replication is initiated in the HEK293T cell culture, 24 hours after infection, the cells are washed and incubated for 48 hours, after which the virus is isolated from the culture; virus passaging for six months in a mixed culture of glioblastoma cells with determination of virus titre and analysis of its cytopathic properties; modification of internal ribosome binding site (IRES), by amplification of IRES using primers SEQ ID NO: 1 and SEQ ID NO: 2, amplification of a DNA fragment coding a genome of a plasmid backbone using primers SEQ ID NO: 3 and SEQ ID NO: 4, with subsequent creation of circular plasmid, which is induced by virus. Invention enables to obtain a highly oncolytic recombinant poliovirus which effectively lyses solid tumours of various histological affiliations. Strain obtained using the disclosed method has shown its effectiveness and safety in experiments in vitro on models of tumour and conditionally normal cell cultures.

EFFECT: optimized recombinant strain has shown high oncolytic activity on various models in vivo in immunodeficient mice with xenografts of human tumours and humanized model of orthotopic rat C6 glioma.

2 cl, 4 dwg, 6 ex